Ono Pharmaceutical Co. Ltd. has entered an option and research collaboration agreement with Monash University to discover and develop antibodies targeting G protein-coupled receptors (GPCRs) with the aim of creating novel therapeutics for the treatment of autoimmune and inflammatory diseases.
Trex Bio Inc. has entered into a multi-year research collaboration and exclusive worldwide license agreement with Eli Lilly & Co. to develop novel therapies for the treatment of immune-mediated diseases.
Kronos Bio Inc. has entered into a discovery collaboration in the field of oncology with Genentech Inc., a member of the Roche Group, focused on discovering and developing small-molecule drugs that modulate transcription factor targets selected by Genentech.
Boehringer Ingelheim Pharma GmbH & Co. KG and 3T Biosciences Inc. have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet needs.
Abbvie Inc. and Immunome Inc. have announced a worldwide collaboration and option agreement for the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome's discovery engine.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. and Hansoh Pharmaceutical Group Company Ltd. have established an antibody collaboration, assignment and exclusive license agreement. Biocytogen will provide a license to Hansoh Pharma for its selected fully human antibody molecules against a designated target for development, manufacturing and commercialization globally.
Peptidream Inc. announced a new multi-target collaboration and license agreement with Merck & Co. Inc., known as MSD outside the U.S. and Canada, as well as research collaboration and license agreement with Eli Lilly & Co (Lilly). Both agreements are focused on the discovery and development of novel peptide drug conjugates (PDCs). Under the agreement with MSD, Peptidream will provide peptide candidates identified from its proprietary Peptide Discovery Platform System (PDPS) technology for use as PDCs against targets of interest to MSD.
Legochem Bioscience Inc. (LCB) has entered into a research collaboration and license agreement with Amgen Inc., granting Amgen rights to research, develop and commercialize antibody-drug conjugates (ADCs) directed against up to 5 targets selected by Amgen based on LCB’s proprietary Conjuall ADC technology.
Insitu Biologics Inc. has entered into an agreement with the Mayo Foundation for Medical Education and Research to further develop its prolonged-release drug delivery technology for cancer therapeutics.
RSS
